UA90380C2 - Фармацевтическая композиция, которая содержит аморфный аторвастатин - Google Patents

Фармацевтическая композиция, которая содержит аморфный аторвастатин

Info

Publication number
UA90380C2
UA90380C2 UAA200809434A UAA200809434A UA90380C2 UA 90380 C2 UA90380 C2 UA 90380C2 UA A200809434 A UAA200809434 A UA A200809434A UA A200809434 A UAA200809434 A UA A200809434A UA 90380 C2 UA90380 C2 UA 90380C2
Authority
UA
Ukraine
Prior art keywords
pharmaceutical composition
amorphous atorvastatin
atorvastatin
bioavailability
atmosphere
Prior art date
Application number
UAA200809434A
Other languages
English (en)
Ukrainian (uk)
Inventor
Рената Яксе
Антон Стімак
Роберт Пісек
Андрей Гартнер
Урос Осепек
Вєсна Крошельй
Original Assignee
Крка, Товарна Здравіл, Д.Д., Ново Мєсто
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Крка, Товарна Здравіл, Д.Д., Ново Мєсто filed Critical Крка, Товарна Здравіл, Д.Д., Ново Мєсто
Publication of UA90380C2 publication Critical patent/UA90380C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к упакованной фармацевтической композиции аторвастатина с улучшенной стабильностью и биодоступностью, где композиция содержит добавку щелочного металла и находится в атмосфере, которая содержит от 1 до 16 об. % кислорода.
UAA200809434A 2006-01-20 2007-01-19 Фармацевтическая композиция, которая содержит аморфный аторвастатин UA90380C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06001232A EP1810667A1 (en) 2006-01-20 2006-01-20 Pharmaceutical composition comprising amorphous atorvastatin

Publications (1)

Publication Number Publication Date
UA90380C2 true UA90380C2 (ru) 2010-04-26

Family

ID=35759155

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200809434A UA90380C2 (ru) 2006-01-20 2007-01-19 Фармацевтическая композиция, которая содержит аморфный аторвастатин

Country Status (6)

Country Link
EP (2) EP1810667A1 (ru)
EA (1) EA014936B1 (ru)
NO (1) NO20083518L (ru)
SI (1) SI1986608T1 (ru)
UA (1) UA90380C2 (ru)
WO (1) WO2007082764A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ300047B6 (cs) * 2007-03-02 2009-01-21 Zentiva, A. S. Farmaceutická kompozice s obsahem úcinné látky atorvastatinu
EP2127628A1 (en) * 2008-05-27 2009-12-02 Ranbaxy Laboratories Limited Unit dose pack
CA2653011A1 (en) * 2008-12-03 2010-06-03 Apotex Technologies Inc Method and apparatus for packaging and dispensing pharmaceuticals
KR20120128599A (ko) 2009-12-25 2012-11-27 사와이세이야쿠 가부시키가이샤 아트로바스타틴 함유 피복 제제
EP3184103A1 (en) * 2015-12-21 2017-06-28 Hexal AG Pharmaceutical composition comprising atorvastatin or a salt thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
WO1994016693A1 (en) 1993-01-19 1994-08-04 Warner-Lambert Company Stable oral ci-981 formulation and process of preparing same
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
HRP960312B1 (en) 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
IL128862A (en) 1995-07-17 2007-12-03 Warner Lambert Co [R - (R * R *)] - 2 - (4 - fluorophenyl) - ß, d - dihydroxy - 5 - (1 - methyl - ethyl) 3 - phenyl - 4 - [(phenamino) carbonyl)] - 1H - Pyrol - 1 - Patenoic acid Hydrogen salt Hydrogen crystalline (Atorostatin) Crystalline hydrate
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
DE19725391A1 (de) * 1997-06-16 1998-12-17 Bayer Ag Verfahren zur Herstellung von Arzneimittel, enthaltend HMG-CoA-Reduktase-Inhibitoren
SI20109A (sl) 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
IN191236B (ru) 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
HU226640B1 (en) 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
PT1235799E (pt) 1999-11-17 2005-05-31 Teva Pharma Forma polimorfica de atorvastatina-calcio
SI20425A (sl) 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
ATE418979T2 (de) 2000-06-09 2009-01-15 Lek Pharmaceuticals Stabilisiertes arzneimittel und arzneizubereitung
IL155734A0 (en) 2000-11-03 2003-11-23 Teve Pharmaceutical Ind Ltd Atorvastatin hemi-calcium form vii
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CZ20032019A3 (cs) 2000-12-27 2003-10-15 Ciba Specialty Chemicals Holding Inc. Krystalické formy Atorvastatinu
WO2002057228A1 (en) 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
EP1336405A1 (en) * 2002-02-14 2003-08-20 Ranbaxy Laboratories, Ltd. Formulations of atorvastatin stabilized with alkali metal additions
CA2385529A1 (en) * 2002-05-21 2003-11-21 Bernard Charles Sherman Stable dosage forms comprising atorvastatin calcium
SI21302A (sl) 2002-10-11 2004-04-30 LEK farmacevtska dru�ba d.d. Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
EP1653930B1 (en) 2003-08-05 2007-12-19 Zentiva, a.s. Methods for the stabilization of atorvastatin

Also Published As

Publication number Publication date
EP1986608A1 (en) 2008-11-05
WO2007082764A1 (en) 2007-07-26
EP1986608B1 (en) 2012-11-21
EA200801572A1 (ru) 2008-10-30
SI1986608T1 (sl) 2013-02-28
EA014936B1 (ru) 2011-04-29
EP1810667A1 (en) 2007-07-25
NO20083518L (no) 2008-10-15

Similar Documents

Publication Publication Date Title
NZ596107A (en) Antiviral compounds and methods
IN2012DN02441A (ru)
TW200716511A (en) New process for the synthesis and new crystalline form of agomelatine and pharmaceutical compositions containing it
MY151003A (en) Stable pharmaceutical composition comprising a pyrimidine-sulfamide
ECSP067110A (es) Derivados de 2-carbamida-4-feniltiazol, su preparación y su aplicación en terapéutica
MX2009003834A (es) Derivados de pirrolidina como inhibidores de iap.
WO2011107186A3 (de) Verbindungen für elektronische vorrichtungen
SG161311A1 (en) Novel use of spiegelmers
TN2011000400A1 (en) Inhibitors of beta-secretase
JO2549B1 (en) Fexofenadine suspension
TW200626564A (en) Carboxylic acid derivative containing thiazole ring and medical use thereof
WO2007077260A8 (en) Formulations of low oil content comprising diphenylmethane derivatives
UA90380C2 (ru) Фармацевтическая композиция, которая содержит аморфный аторвастатин
PT2323972E (pt) Compostos de tetraciclina substituídos com c7-flúor
TW200833657A (en) Novel process
WO2007019191A3 (en) Thiazolopyrimidine kinase inhibitors
IN2012DN02502A (ru)
NO20085317L (no) Imidazoazepinonforbindelser
MY148393A (en) Malate salts, and polymorphs of (3s, 5s)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid
WO2006031929A3 (en) Thiazolopyridine kinase inhibitors
GR20050100466A (el) Βελτιωμενες φαρμακευτικες συνθεσεις που περιεχουναναστολεις της αναγωγασης του 3-υδροξυ-3-μεθυλογλουταρυλοσυνενζυμου α (hmg-coa) και μεθοδος παρασκευης αυτων
MX2010000693A (es) Composicion farmaceutica que comprende un compuesto de 11-desoxi-prostaglandina y metodo para establilizar el compuesto.
HU0402466D0 (en) Industrial process for preparing 17-hydroxy-6-betha, 7-betha, 15-betha, 16-betha-bis-methylene-3-oxo-17-alpha-pregn-4-ene-21-carboxylic acid gamma lacton and the main, intermediates of the process
IL194094A0 (en) Stable pharmacuetical compositions of 2-aza-bicyclol[3.3.0]-octane-3-carboxylic acid derivatives
TW200531693A (en) Prolonged-release diuretic compositions